THTakanori Hayashi

Takanori Hayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takanori Hayashi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Nobuhiro Harada

    Department of Biochemistry Fujita Health University School of Medicine Toyoake Japan

    4 shared publications
  • Eiji Nishio

    Department of Obstetrics and Gynecology Fujita Health University School of Medicine Toyoake Japan

    3 shared publications
  • Yohei Shimono

    Department of Biochemistry Fujita Health University School of Medicine Toyoake Japan

    3 shared publications
  • Masahiro Hikichi

    Department of Breast Surgery Fujita Health University School of Medicine Toyoake Japan

    2 shared publications
  • Shinichiro Honda

    Department of Biochemistry Fukuoka School of Pharmaceutical Sciences, Fukuoka University Japan

    2 shared publications
  • Takuma Fujii

    Department of Obstetrics and Gynecology Fujita Health University School of Medicine Toyoake Japan

    2 shared publications

Latest Publications

  • Open Access

    Estrogen synthesized in the central nervous system enhances MC4R expression and reduces food intake

    by Takanori Hayashi, Kanako Kumamoto, Tatsuya Kobayashi, Xinfeng Hou, Shizuko Nagao, Nobuhiro Harada, Shinichiro Honda, Yohei Shimono, Eiji Nishio

    Estrogen is synthesized throughout various tissues in the body, and its production is regulated by the rate‐limiting enzyme aromatase (encoded by the Cyp19a1 gene). Notably, aromatase is also expressed in central nervous system cells, allowing for localized estrogen synthesis in regions such as the hypothalamus. Estrogens produced within these neurons are referred to as neuroestrogens. In this study, we investigated the role of neuroestrogens in the regulation of appetite through modulation of hypothalamic pathways in OVX, ArKO, and aromatase‐restored mice. Estrogen suppresses appetite by influencing the expression of appetite‐regulating peptides, including POMC and NPY, via MC4R. We explored the direct effects of neuroestrogens, independent from ovarian estrogen, on appetite suppression and the underlying molecular mechanisms. We monitored body weight and food intake and evaluated the expression of Cyp19a1, Mc4r, and other appetite‐related genes. Our findings indicate that OVX and ArKO mice exhibited increased body weight and food consumption, which correlated with altered expression of Mc4r and Cyp19a1. Conversely, restoration of Cyp19a1 expression in a neuron specific manner significantly decreased food intake and increased Mc4r expression in the hypothalamus. Furthermore, neuroestrogens enhanced leptin responsiveness. Our results imply that neuroestrogens likely contribute to appetite regulation and may be relevant for body weight reduction.


  • Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study

    by Takanori Hayashi, Naomi Kobayashi, Kaori Ushida, Naoya Asai, Shogo Nakano, Kimihito Fujii, Takahito Ando, Toshiaki Utsumi

    Epithelial-mesenchymal transition (EMT) plays a pivotal role in cancer metastasis and treatment resistance, which worsens prognosis. In phase III trials, eribulin improved overall survival in metastatic breast cancer (MBC) patients. In preclinical studies, eribulin suppressed EMT. However, clinical data on the use of eribulin for MBC patients are limited. In this exploratory, prospective study, we examined the effect of eribulin on EMT in MBC patients. Twenty-two patients aged 44-82 years with recurrent breast cancer or MBC were treated with eribulin. Breast cancer tissue samples were obtained before treatment and on Day 15 +/- 5 of the first cycle of eribulin treatment. EMT markers (E-cadherin, claudin-3, vimentin, and N-cadherin) were analyzed using western blotting. EMT changes were evaluated based on the ratio of epithelial to mesenchymal markers before and after treatment in individual tumors. E-cadherin/vimentin, claudin-3/vimentin, E-cadherin/N-cadherin, and claudin-3/ N-cadherin ratios were significantly higher after treatment (p = .007, p = .005, p = .006, and p = .011, respectively). Based on E-cadherin/vimentin, 65.0% of tumors shifted to an epithelial phenotype, as compared to 66.7% based on claudin-3/vimentin, 84.6% based on E-cadherin/N-cadherin, and 71.4% based on claudin-3/N-cadherin ratios. Thus, our results showed that eribulin suppressed EMT in breast cancer tissues.


  • Open Access

    Adipsin-Dependent Secretion of Hepatocyte Growth Factor Regulates the Adipocyte-Cancer Stem Cell Interaction

    by Masahiro Mizuno, Behnoush Khaledian, Masao Maeda, Takanori Hayashi, Seiya Mizuno, Eiji Munetsuna, Takashi Watanabe, Seishi Kono, Seiji Okada, Motoshi Suzuki, et al.

    Adipose tissue is a component of the tumor microenvironment and is involved in tumor progression. We have previously shown that adipokine adipsin (CFD) functions as an enhancer of tumor proliferation and cancer stem cell (CSC) properties in breast cancers. We established the Cfd-knockout (KO) mice and the mammary adipose tissue-derived stem cells (mADSCs) from them. Cfd-KO in mADSCs significantly reduced their ability to enhance tumorsphere formation of breast cancer patient-derived xenograft (PDX) cells, which was restored by the addition of Cfd in the culture medium. Hepatocyte growth factor (HGF) was expressed and secreted from mADSCs in a Cfd-dependent manner. HGF rescued the reduced ability of Cfd-KO mADSCs to promote tumorsphere formation in vitro and tumor formation in vivo by breast cancer PDX cells. These results suggest that HGF is a downstream effector of Cfd in mADSCs that enhances the CSC properties in breast cancers.


  • Open Access

    Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus

    by Eiji Nishio, Takanori Hayashi, Mao Akaza, Yukiko Hisatomi, Masahiro Hikichi, Takuma Fujii, Toshiaki Utsumi, Nobuhiro Harada, Yohei Shimono

    Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A) is a human oncoprotein that can promote cancer cell growth and apoptosis resistance. Although CIP2A is upregulated in hormone‐related cancers, such as breast cancer, little is known about potential anti‐tumor effects of downregulating CIP2A. As a model to study the resistance of breast cancer cells to hormone treatment, we previously established clones of long‐term estrogen depletion‐resistant MCF‐7 (LTED) cells. Here, we selected three clones highly responsive to EVE and three clones poorly responsive to EVE. When cells were treated with EVE, CIP2A mRNA expression was decreased in highly responsive EVE clones (DC‐cells) whereas it was increased in poorly responsive EVE clones (IC‐cells). Using Kaplan–Meier survival plots, we report that high expression of CIP2A was associated with significantly reduced overall survival in patients with luminal A breast cancer. In IC‐cells, cell growth was enhanced upon EVE treatment whereas an EVE range of 0.1–100 nm decreased growth in DC‐cells. The mRNA expression of genes involved in epithelial–mesenchymal transition (EMT) such as CDH1, CLDN3, and CK19 was significantly decreased in IC‐cells, but remained unchanged in DC‐cells. These findings highlight a relationship between CIP2A and EMT in the intrinsic resistance of hormone therapy‐resistant breast cancers to EVE.


  • Open Access

    Lack of association of ovariectomy-induced obesity with overeating and the reduction of physical activities

    by Eiji Nishio, Takanori Hayashi, Masashi Nakatani, Noriko Aida, Risa Suda, Takuma Fujii, Toru Wakatsuki, Shinichiro Honda, Nobuhiro Harada, Yohei Shimono


  • Open Access

    Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells

    by Takanori Hayashi, Masahiro Hikichi, Jun Yukitake, Toru Wakatsuki, Eiji Nishio, Toshiaki Utsumi, Nobuhiro Harada

    Oncotarget | https://doi.org/10.18632/oncotarget.25217 Takanori Hayashi, Masahiro Hikichi, Jun Yukitake, Toru Wakatsuki, Eiji Nishio, Toshiaki Utsumi, Nobuhiro Harada Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells


  • Open Access

    Liquid crystal formation control of polymer-liquid crystal mixtures by photoisomerization of azobenzene moiety.

    by Yoshihiko Onogi, Takanori Hayashi, Yasuyuki Mizushima, Masahide Yamamoto

    アゾベンゼン構造を側鎖にもつ感光性高分子を調製し,低分子液晶と混合した系の液晶形成能を測定した。p-トキシアゾベンゼンと低分子液晶との混合系と同様に,アゾベンゼン構造の濃度とともに直線的に系の液晶形成濃度範囲が減少した。アゾベンゼン構造が液晶中に存在しうることにより,柔軟な高分子鎖も液晶中に分散することがわかった。さらに,高分子鎖の液晶阻害効果はアゾベンゼンよりも大きいことが推測できた。いま,光照射によりアゾベンゼン構造をトランス体からシス体へと変化させると,液晶形成温度領域が減少することが確認された。すなわち,低分子混合液晶系と同様,光により系の液晶形成を制御可能であることが確かめられた。光マスクを用いて光記録を試みたところ,記録豫の経時安定性において,低分子混合系よりもいちじるしい改善がみられた。